FA
CHRS icon

Friess Associates’s Coherus Oncology CHRS Stock Holding History

Friess Associates’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-97,932
Closed -$1.8M – 100
2020
Q3 		$1.8M Sell
97,932
-5,268
-5% -$98K 0.16% 84
2020
Q2 		$1.84M Sell
103,200
-187,380
-64% -$3.17M 0.17% 82
2020
Q1 		$4.71M Buy
+290,580
New +$5.37M 0.47% 62

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Friess Associates's CHRS Position: Q4 2020 in Review

Friess Associates sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 97,932 shares — an estimated $1.8M sold.

Friess Associates first reported a position in CHRS in Q1 2020 and held it in 3 quarters. The position peaked at $4.71M in Q1 2020. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

  • Friess Associates reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
  • Friess Associates sold 97,932 Coherus Oncology shares in Q4 2020, an estimated $1.8M.
  • Friess Associates first reported a position in Coherus Oncology in Q1 2020 and held it in 3 quarters.
  • Friess Associates's Coherus Oncology position peaked at $4.71M in Q1 2020.
  • 196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on Friess Associates's 13F filing for Q4 2020, filed 12 Feb 2021.